Evoke Pharma Q1 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate, Sales $1.74M Miss $2.14M Estimate
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma reported Q1 2024 earnings with a GAAP EPS of $(0.17), surpassing the $(0.21) estimate. However, their sales of $1.74M fell short of the $2.14M estimate, despite being a 114.09% increase from the previous year.
May 14, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Evoke Pharma's Q1 2024 earnings exceeded EPS estimates but missed on sales forecasts, showing significant year-over-year growth.
The mixed results of beating EPS estimates but missing sales forecasts could lead to neutral market reaction. The significant year-over-year sales growth indicates strong business growth, which might offset concerns about the sales miss.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100